Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,500JPY
11:30am IST
Change (% chg)

¥-4 (-0.23%)
Prev Close
¥1,504
Open
¥1,496
Day's High
¥1,516
Day's Low
¥1,492
Volume
5,674,500
Avg. Vol
6,025,942
52-wk High
¥2,056
52-wk Low
¥1,356

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main... (more)

Overall

Beta: 0.69
Market Cap(Mil.): ¥2,774,681.00
Shares Outstanding(Mil.): 1,888.82
Dividend: 20.00
Yield (%): 2.59

Financials

  4503.T Industry Sector
P/E (TTM): 12.82 32.51 37.25
EPS (TTM): 114.62 -- --
ROI: 15.67 12.52 12.15
ROE: 17.59 13.83 16.99

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

03 Jun 2019

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

03 Jun 2019

UPDATE 1-Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

03 Jun 2019

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

03 Jun 2019

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

26 Apr 2019

UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

26 Apr 2019

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications, the U.S. Justice Department said on Thursday.

25 Apr 2019

Earnings vs. Estimates